{"nctId":"NCT01939197","briefTitle":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","startDateStruct":{"date":"2013-08-30"},"conditions":["Hepatitis C Virus Infection","Human Immunodeficiency Virus Infection","Chronic Hepatitis C","Compensated Cirrhosis and Non-cirrhotics"],"count":318,"armGroups":[{"label":"ARM A","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333","Drug: ribavirin"]},{"label":"ARM B","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333","Drug: ribavirin"]},{"label":"ARM C","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333","Drug: ribavirin"]},{"label":"ARM D","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333","Drug: ribavirin"]},{"label":"ARM E","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333"]},{"label":"ARM F","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333"]},{"label":"ARM G","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333","Drug: ribavirin"]},{"label":"ARM H","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333","Drug: ribavirin"]},{"label":"ARM I","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333","Drug: ribavirin"]},{"label":"ARM J","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ABT-333","Drug: ribavirin"]},{"label":"ARM K","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ribavirin"]},{"label":"ARM L","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-450/r/ABT-267","Drug: ribavirin"]}],"interventions":[{"name":"ABT-450/r/ABT-267","otherNames":["ombitasvir/paritaprevir/ritonavir","ombitasvir also known as ABT-267","paritaprevir also known as ABT-450"]},{"name":"ABT-333","otherNames":["Dasabuvir"]},{"name":"ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic HCV infection at screening defined as: positive anti-HCV antibodies (Ab) at screening and HCV RNA \\> 1,000 IU/mL at screening.\n* Plasma HIV-1 RNA \\< 40 copies/mL during screening using Abbott RealTime HIV-1 assay.\n* On a stable qualifying HIV-1 antiretroviral therapy regimen.\n\nExclusion Criteria:\n\n* Positive test result at screening for hepatitis B surface antigen.\n* Evidence of HCV genotype other than genotype 1 or genotype 4 during screening.\n* Receipt of any other investigational or commercially available anti-HCV agents (for example, telaprevir, boceprevir, simeprevir, daclatasvir and ledipasvir) with the exception of interferon (including pegylated-interferon alfa-2a or alfa-2b), sofosbuvir and ribavirin.\n* Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT-450, ABT-267, ABT-333, ritonavir or ribavirin.\n* Chronic human immunodeficiency virus, type 2 (HIV-2) infection.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants in GT1 Analysis Group 1 in Part 2 Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12)","description":"SVR12 is defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (\\< LLOQ) 12 weeks after the last dose of study drug without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% confidence interval (CI) is calculated using the Wilson score method for binomial distribution.\n\nThe primary efficacy endpoint was the non-inferiority of the percentage of participants in the GT1 Analysis Group in Part 2 achieving SVR12 compared to the historical SVR12 rate for sofosbuvir plus ribavirin (a non-inferiority threshold of the lower bound of the 95% CI of 74%).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 1a Achieving SVR12","description":"SVR12 is defined as plasma HCV RNA \\< LLOQ 12 weeks after the last dose of study drug without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% CI is calculated using the Wilson score method for binomial distribution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null},{"groupId":"OG001","value":"90.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 1b Achieving SVR12","description":"SVR12 is defined as plasma HCV RNA \\< LLOQ 12 weeks after the last dose of study drug without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% CI is calculated using the Wilson score method for binomial distribution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Arm F and Arm G of Part 2 Achieving SVR12","description":"SVR12 is defined as plasma HCV RNA \\< LLOQ 12 weeks after the last dose of study drug without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% CI is calculated using the Wilson score method for binomial distribution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With GT4 HCV in Part 2 Achieving SVR12, by Arm and Overall","description":"SVR12 is defined as plasma HCV RNA \\< LLOQ 12 weeks after the last dose of study drug without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% CI is calculated using the Wilson score method for binomial distribution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"96.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 1a With On-Treatment HCV Virologic Failure During the Treatment Period","description":"Percentage of participants with on-treatment HCV virologic failure during the treatment period for each arm in Part 1a. Virologic failure is defined as confirmed quantifiable HCV RNA among participants with previously unquantifiable HCV RNA during treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 1b With On-Treatment HCV Virologic Failure During the Treatment Period","description":"Percentage of participants with on-treatment HCV virologic failure during the treatment period for each arm and overall in Part 1b. Virologic failure is defined as confirmed quantifiable HCV RNA among participants with previously unquantifiable HCV RNA during treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 2 With On-Treatment HCV Virologic Failure During the Treatment Period","description":"Percentage of participants with on-treatment HCV virologic failure during the treatment period for arms in Part 2. Virologic failure is defined as confirmed quantifiable HCV RNA among participants with previously unquantifiable HCV RNA during treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"25.0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 1a With Relapse12","description":"Percentage of participants who experienced Relapse12 among participants who completed treatment with HCV RNA \\< LLOQ at final treatment visit and had at least one post-treatment HCV RNA value. Relapse12 is defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug (up to and including the SVR12 assessment time point) for a participant with HCV RNA \\< LLOQ at final treatment visit who completed treatment and had post-treatment data. Completion of treatment is defined as study drug duration ≥ 77 days for Arm A and ≥ 154 days for Arm B. The 95% CI is calculated using Wilson score method for the binomial distribution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 1b With Relapse12 for Each Arm and Overall","description":"Percentage of participants who experienced Relapse12 among participants who completed treatment with HCV RNA \\< LLOQ at final treatment visit and had at least one post-treatment HCV RNA value. Relapse12 is defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug (up to and including the SVR12 assessment time point) for a participant with HCV RNA \\< LLOQ at final treatment visit who completed treatment and had post-treatment data. Completion of treatment is defined as study drug duration ≥ 77 days for Arm C and Arm D. The 95% CI is calculated using Wilson score method for the binomial distribution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 2 With Relapse12","description":"Percentage of participants who experienced Relapse12 among those who completed treatment with HCV RNA \\< LLOQ at final treatment visit and had ≥1 post-treatment HCV RNA value. Relapse12=confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug (up to and including the SVR12 window) for a participant with HCV RNA \\< LLOQ at final treatment visit who completed treatment and had post-treatment data, excluding reinfection. Completion of treatment=study drug duration ≥ 77 days for participants who received 12 weeks of treatment and ≥154 days for participants who received 24 weeks of treatment. HCV reinfection=confirmed HCV RNA ≥ LLOQ after the end of treatment in a subject who had HCV RNA \\< LLOQ at final treatment visit, along with the post-treatment detection of a different HCV genotype, subtype, or clade compared with baseline, as determined by phylogenetic analysis. The 95% CI is calculated using Wilson score method for the binomial distribution.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0.8","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 1a With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment","description":"HIV virologic success was defined as HIV-1 RNA suppression (HIV-1 RNA value \\< 40 copies/mL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null},{"groupId":"OG001","value":"90.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"93.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 1b With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment","description":"HIV virologic success was defined as HIV-1 RNA suppression (HIV-1 RNA value \\< 40 copies/mL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"83.3","spread":null},{"groupId":"OG002","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"86.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Part 2 With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment","description":"HIV virologic success was defined as HIV-1 RNA suppression (HIV-1 RNA value \\< 40 copies/mL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"90.5","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"89.6","spread":null},{"groupId":"OG004","value":"78.9","spread":null},{"groupId":"OG005","value":"85.7","spread":null},{"groupId":"OG006","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"97.6","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"91.9","spread":null},{"groupId":"OG004","value":"89.5","spread":null},{"groupId":"OG005","value":"92.9","spread":null},{"groupId":"OG006","value":"92.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["FATIGUE","NAUSEA","HEADACHE","INSOMNIA","DIARRHOEA"]}}}